Expansion of Umbilical Cord Blood Aldehyde Dehydrogenase Expressing Cells Generates Myeloid Progenitor Cells that Stimulate Limb Revascularization
David M Putman, Tyler T Cooper, Stephen E Sherman, Ayesh K Seneviratne, Mark Hewitt, Gillian I Bell, David A Hess, David M Putman, Tyler T Cooper, Stephen E Sherman, Ayesh K Seneviratne, Mark Hewitt, Gillian I Bell, David A Hess
Abstract
Uncompromised by chronic disease-related comorbidities, human umbilical cord blood (UCB) progenitor cells with high aldehyde dehydrogenase activity (ALDHhi cells) stimulate blood vessel regeneration after intra-muscular transplantation. However, implementation of cellular therapies using UCB ALDHhi cells for critical limb ischemia, the most severe form of severe peripheral artery disease, is limited by the rarity (<0.5%) of these cells. Our goal was to generate a clinically-translatable, allogeneic cell population for vessel regenerative therapies, via ex vivo expansion of UCB ALDHhi cells without loss of pro-angiogenic potency. Purified UCB ALDHhi cells were expanded >18-fold over 6-days under serum-free conditions. Consistent with the concept that ALDH-activity is decreased as progenitor cells differentiate, only 15.1% ± 1.3% of progeny maintained high ALDH-activity after culture. However, compared to fresh UCB cells, expansion increased the total number of ALDHhi cells (2.7-fold), CD34+ /CD133+ cells (2.8-fold), and hematopoietic colony forming cells (7.7-fold). Remarkably, injection of expanded progeny accelerated recovery of perfusion and improved limb usage in immunodeficient mice with femoral artery ligation-induced limb ischemia. At 7 or 28 days post-transplantation, mice transplanted with expanded ALDHhi cells showed augmented endothelial cell proliferation and increased capillary density compared to controls. Expanded cells maintained pro-angiogenic mRNA expression and secreted angiogenesis-associated growth factors, chemokines, and matrix modifying proteins. Coculture with expanded cells augmented human microvascular endothelial cell survival and tubule formation under serum-starved, growth factor-reduced conditions. Expanded UCB-derived ALDHhi cells represent an alternative to autologous bone marrow as an accessible source of pro-angiogenic hematopoietic progenitor cells for the refinement of vascular regeneration-inductive therapies. Stem Cells Translational Medicine 2017;6:1607-1619.
Keywords: Aldehyde dehydrogenase; Angiogenesis; Hematopoietic progenitor cell expansion; Peripheral artery disease; Transplantation; Umbilical cord blood.
© 2017 The Authors Stem Cells Translational Medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
Figures
References
- Lackland DT, Roccella EJ, Deutsch AF et al. Factors influencing the decline in stroke mortality: A statement from the American Heart Association/American Stroke Association. Stroke 2014;45:315–353.
- Dotsenko O. Stem/Progenitor cells, atherosclerosis and cardiovascular regeneration. Open Cardiovasc Med J 2010;4:97–104.
- Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964–967.
- Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: The scientific foundations of cardiac repair. J Clin Invest 2005;115:572–583.
- Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003;9:702–712.
- Michler RE. Stem cell therapy for heart failure. Cardiol Rev 2014;22:105–116.
- Gupta NK, Armstrong EJ, Parikh SA. The current state of stem cell therapy for peripheral artery disease. Curr Cardiol Rep 2014;16:447.
- Botham CM, Bennett WL, Cooke JP. Clinical trials of adult stem cell therapy for peripheral artery disease. Methodist DeBakey Cardiovasc J 2013;9:201–205.
- Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701–705.
- Murray CE, Soonpas MH, Reinecke H et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004;664–668.
- Balsam LB, Wagers AJ, Christensen LJ et al. Hematopoietic stem cells adopt mature hematopoietic fates in ischemic myocardium. Nature 2004;428:668–673.
- Rosenzweig A. Cardiac cell therapy–mixed results from mixed cells. N Engl J Med 2006;355:1274–1277.
- Janssens S, Dubois C, Bogaert J et al. Autologous bone marrow‐derived stem‐cell transfer in patients with ST‐segment elevation myocardial infarction: Double‐blind, randomised controlled trial. Lancet 2006;367:113–121.
- Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bone‐marrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial. Lancet 2004;364:141–148.
- Schachinger V, Erbs S, Elsässer A et al. Intracoronary bone marrow‐derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210–1221.
- Tateishi‐Yuyama E, Matsubara H, Murohara T et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone‐marrow cells: A pilot study and a randomised controlled trial. Lancet 2002;360:427–435.
- Higashi Y, Kimura M, Hara K et al. Autologous bone‐marrow mononuclear cell implantation improves endothelium‐dependent vasodilation in patients with limb ischemia. Circulation 2004;109:1215–1218.
- Peichev M, Naiyer AJ, Pereira D et al. Expression of VEGFR‐2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952–958.
- Schatteman GC, Hanlon HD, Jiao C et al. Blood‐derived angioblasts accelerate blood‐flow restoration in diabetic mice. J Clin Invest 2000;106:571–578.
- Urbich C, Heeschen C, Aicher A et al. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003;108:2511–2516.
- Yoder MC, Mead LE, Prater D et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007;109:1801–1809.
- Capoccia BJ, Robson DL, Levac KD et al. Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity. Blood 2009;113:5340–5351.
- Hess DA, Craft TP, Wirthlin L et al. Widespread nonhematopoietic tissue distribution by transplanted human progenitor cells with high aldehyde dehydrogenase activity. Stem Cells 2008;26:611–620.
- Wara AK, Croce K, Foo S et al. Bone marrow‐derived CMPs and GMPs represent highly functional proangiogenic cells: Implications for ischemic cardiovascular disease. Blood 2011;118:6461–6464.
- Okuno Y, Nakamura‐Ishizu A, Kishi K et al. Bone marrow‐derived cells serve as proangiogenic macrophages but not endothelial cells in wound healing. Blood 2011;117:5264–5272.
- Ohtani K, Vlachojannis GJ, Koyanagi M et al. Epigenetic regulation of endothelial lineage committed genes in pro‐angiogenic hematopoietic and endothelial progenitor cells. Circ Res 2011;109:1219–1229.
- Grunewald M, Avraham I, Dor Y et al. VEGF‐induced adult neovascularization: Recruitment, retention, and role of accessory cells. Cell 2006;124:175–189.
- Putman DM, Liu KY, Broughton HC et al. Umbilical cord blood‐derived aldehyde dehydrogenase‐expressing progenitor cells promote recovery from acute ischemic injury. Stem Cells 2012;30:2248–2260.
- Perin EC, Silva G, Gahremanpour A et al. A randomized, controlled study of autologous therapy with bone marrow‐derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia. Catheter Cardiovasc Interv 2011;78:1060–1067.
- Vasa M, Fichtlscherer S, Aicher A et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89:E1–E7.
- Tepper OM, Carr J, Allen RJ Jr. et al. Decreased circulating progenitor cell number and failed mechanisms of stromal cell‐derived factor‐1alpha mediated bone marrow mobilization impair diabetic tissue repair. Diabetes 2010;59:1974–1983.
- Fadini GP, Sartore S, Albiero M et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 2006;26:2140–2146.
- Jialal I, Devaraj S, Singh U et al. Decreased number and impaired functionality of endothelial progenitor cells in subjects with metabolic syndrome: Implications for increased cardiovascular risk. Atherosclerosis 2010. ; 211:297–302.
- Perin EC, Murphy M, Cooke JP et al. Rationale and design for PACE: Patients with Intermittent claudication injected with ALDH bright cells. American Heart J 2014;168:667–673.
- Bhatia M, Bonnet D, Kapp U et al. Quantitative analysis reveals expansion of human hematopoietic repopulating cells after short‐term expansion. J.Exp Med 1997;186:619–624.
- Chute JP, Muramoto GG, Whitesides J et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci USA 2006;103:11707–11712.
- Boitano AE, Wang J, Romeo R et al. Aryl hydrocarbon receptor antagonist promotes the expansion of human hematopoietic stem cells. Science 2011;329:1345–1348.
- Csaszar E, Kirouac DC, Yu M et al. Rapid expansion of human hematopoietic stem cells by automated control of inhibitory feedback signaling. Cell Stem Cell 2012;10:218–229.
- Dahlberg A, Delaney C, Bernstein ID. Ex vivo expansion of human hematopoietic stem and progenitor cells. Blood 2011;117:6083–6090.
- Seneviratne AK, Bell GI, Sherman SE et al. Expanded hematopoietic progenitor cells with high aldehyde dehydrogenase activity demonstrate islet regenerative functions. Stem Cells 2016;34:873–887.
- Perin EC, Silva GV, Zheng Y et al. Randomized, double‐blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase‐bright stem cells in patients with ischemic heart failure. Am. Heart J 2012;163:415–21–421.e1.
- Berezin AE, Kremzer AA. Circulating endothelial progenitor cells as markers for severity of ischemic chronic heart failure. J Card Fail 2014;6:438–447.
- Eklund L, Saharinen P. Angiopoietin signaling in the vasculature. Exp Cell Res 2013;319:1271–1280.
- Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298–307.
- Zhang F, Tang Z, Hou X et al. VEGF‐B is dispensable for blood vessel growth but critical for their survival, and VEGF‐B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA 2009;106:6152–6157.
- Holash J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994–1998.
- Stanic B, Pandey D, Fulton DJ et al. Increased epidermal growth factor‐like ligands are associated with elevated vascular nicotinamide adenine dinucleotide phosphate oxidase in a primate model of atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:2452–2460.
- Kato M, Inazu T, Kawai Y et al. Amphiregulin is a potent mitogen for the vascular smooth muscle cell line, A7r5. Biochem Biophys Res Commun 2003;301:1109–1115.
- Dreux AC, Lamb DJ, Modjtahedi H et al. The epidermal growth factor receptors and their family of ligands: Their putative role in atherogenesis. Atherosclerosis 2006;186:38–53.
- Makki N, Thiel K, Miller F. The epidermal growth factor receptor and its ligands in cardiovascular disease. IJMS 2013;14:20597–20613.
- Fiedler U, Scharpfenecker M, Koidl S et al. The Tie‐2 ligand angiopoietin‐2 is stored in and rapidly released upon stimulation from endothelial cell Weibel‐Palade bodies. Blood 2004;103:4150–4156.
- Fiedler U, Augustin HG. Angiopoietins: A link between angiogenesis and inflammation. Trends Immunol 2006;27:552–558.
- Crola Da Silva C, Lamerant‐Fayel N et al. Selective human endothelial cell activation by chemokines as a guide to cell homing. Immunology 2009;126:394–404.
Source: PubMed